| Dr Madhavi Kadiyala, MD | |
|
1 Medical Center Dr, Morgantown, WV 26506 | |
| (304) 598-4000 | |
| Not Available |
| Full Name | Dr Madhavi Kadiyala |
|---|---|
| Gender | Female |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 26 Years |
| Location | 1 Medical Center Dr, Morgantown, West Virginia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013182377 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Tufts Medical Center | Boston, MA | Hospital |
| Melrosewakefield Healthcare | Melrose, MA | Hospital |
| Sturdy Memorial Hospital | Attleboro, MA | Hospital |
| Southcoast Hospitals Group | Fall river, MA | Hospital |
| Metrowest Medical Center | Framingham, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cardiovascular Center At Tufts Medical Center Inc | 3870857816 | 96 |
| Southcoast Hospitals Group, Inc. | 1850282310 | 21 |
News Archive
Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced that the company has initiated a Phase I clinical study for ETC-1002, the company's novel small molecule compound designed to beneficially regulate the levels of plasma lipids and lipoproteins.
A protein previously thought to merely hinder the activity of a key cellular protein linked to cancer cell death, now appears to mimic the cellular signaling of that protein; potentially leading to the development of lymphoma.
The rate of gestational diabetes has shot up 30 percent in young U.S. women over the past decade and more than doubled in U.S. women who identify as Asian-Indian compared with non-Hispanic White women, reports a new Northwestern Medicine study published in JAMA.
The Executive Order President Obama issued Monday directing the U.S. Food and Drug Administration to take action to reduce prescription drug shortages is a commendable first step, but the White House could strengthen its directive and address the full scope of the problem by ordering mandatory reporting by manufacturers, which The Endocrine Society calls for in its Position Statement on drug shortages.
MorphoSys AG and Boehringer Ingelheim announced today the signing of a biopharmaceutical manufacturing agreement for therapeutic antibodies. The agreement covers the process development and manufacturing of additional clinical material for MorphoSys's proprietary MOR208 program and other drug candidates. MOR208, a potent monoclonal anti-CD19 antibody, is in development for the treatment of chronic lymphocytic leukemia and potentially other B-cell malignancies. The program is currently being evaluated in a phase 1 clinical trial in the USA by MorphoSys's partner Xencor Inc.
› Verified 8 days ago
| Entity Name | Southcoast Hospitals Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306871223 PECOS PAC ID: 1850282310 Enrollment ID: O20041214000621 |
News Archive
Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced that the company has initiated a Phase I clinical study for ETC-1002, the company's novel small molecule compound designed to beneficially regulate the levels of plasma lipids and lipoproteins.
A protein previously thought to merely hinder the activity of a key cellular protein linked to cancer cell death, now appears to mimic the cellular signaling of that protein; potentially leading to the development of lymphoma.
The rate of gestational diabetes has shot up 30 percent in young U.S. women over the past decade and more than doubled in U.S. women who identify as Asian-Indian compared with non-Hispanic White women, reports a new Northwestern Medicine study published in JAMA.
The Executive Order President Obama issued Monday directing the U.S. Food and Drug Administration to take action to reduce prescription drug shortages is a commendable first step, but the White House could strengthen its directive and address the full scope of the problem by ordering mandatory reporting by manufacturers, which The Endocrine Society calls for in its Position Statement on drug shortages.
MorphoSys AG and Boehringer Ingelheim announced today the signing of a biopharmaceutical manufacturing agreement for therapeutic antibodies. The agreement covers the process development and manufacturing of additional clinical material for MorphoSys's proprietary MOR208 program and other drug candidates. MOR208, a potent monoclonal anti-CD19 antibody, is in development for the treatment of chronic lymphocytic leukemia and potentially other B-cell malignancies. The program is currently being evaluated in a phase 1 clinical trial in the USA by MorphoSys's partner Xencor Inc.
› Verified 8 days ago
| Entity Name | Cardiovascular Center At Tufts Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447764253 PECOS PAC ID: 3870857816 Enrollment ID: O20180430000179 |
News Archive
Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced that the company has initiated a Phase I clinical study for ETC-1002, the company's novel small molecule compound designed to beneficially regulate the levels of plasma lipids and lipoproteins.
A protein previously thought to merely hinder the activity of a key cellular protein linked to cancer cell death, now appears to mimic the cellular signaling of that protein; potentially leading to the development of lymphoma.
The rate of gestational diabetes has shot up 30 percent in young U.S. women over the past decade and more than doubled in U.S. women who identify as Asian-Indian compared with non-Hispanic White women, reports a new Northwestern Medicine study published in JAMA.
The Executive Order President Obama issued Monday directing the U.S. Food and Drug Administration to take action to reduce prescription drug shortages is a commendable first step, but the White House could strengthen its directive and address the full scope of the problem by ordering mandatory reporting by manufacturers, which The Endocrine Society calls for in its Position Statement on drug shortages.
MorphoSys AG and Boehringer Ingelheim announced today the signing of a biopharmaceutical manufacturing agreement for therapeutic antibodies. The agreement covers the process development and manufacturing of additional clinical material for MorphoSys's proprietary MOR208 program and other drug candidates. MOR208, a potent monoclonal anti-CD19 antibody, is in development for the treatment of chronic lymphocytic leukemia and potentially other B-cell malignancies. The program is currently being evaluated in a phase 1 clinical trial in the USA by MorphoSys's partner Xencor Inc.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Madhavi Kadiyala, MD 1 Medical Center Dr, Morgantown, WV 26506-1200 Ph: () - | Dr Madhavi Kadiyala, MD 1 Medical Center Dr, Morgantown, WV 26506 Ph: (304) 598-4000 |
News Archive
Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced that the company has initiated a Phase I clinical study for ETC-1002, the company's novel small molecule compound designed to beneficially regulate the levels of plasma lipids and lipoproteins.
A protein previously thought to merely hinder the activity of a key cellular protein linked to cancer cell death, now appears to mimic the cellular signaling of that protein; potentially leading to the development of lymphoma.
The rate of gestational diabetes has shot up 30 percent in young U.S. women over the past decade and more than doubled in U.S. women who identify as Asian-Indian compared with non-Hispanic White women, reports a new Northwestern Medicine study published in JAMA.
The Executive Order President Obama issued Monday directing the U.S. Food and Drug Administration to take action to reduce prescription drug shortages is a commendable first step, but the White House could strengthen its directive and address the full scope of the problem by ordering mandatory reporting by manufacturers, which The Endocrine Society calls for in its Position Statement on drug shortages.
MorphoSys AG and Boehringer Ingelheim announced today the signing of a biopharmaceutical manufacturing agreement for therapeutic antibodies. The agreement covers the process development and manufacturing of additional clinical material for MorphoSys's proprietary MOR208 program and other drug candidates. MOR208, a potent monoclonal anti-CD19 antibody, is in development for the treatment of chronic lymphocytic leukemia and potentially other B-cell malignancies. The program is currently being evaluated in a phase 1 clinical trial in the USA by MorphoSys's partner Xencor Inc.
› Verified 8 days ago
Rohma Shamsi, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 1 Medical Center Drive, Morgantown, WV 26506 Phone: 304-293-4125 | |
Islam Younes, Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 1 Medical Center Dr, Morgantown, WV 26506 Phone: 855-988-2273 | |
Dr. David Weissman, M. D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 1 Stadium Drive, Morgantown, WV 26506 Phone: 304-598-4800 Fax: 304-293-6963 | |
Dr. Swapna Gayam, M.D Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Drive, Morgantown, WV 26506 Phone: 304-293-4123 Fax: 304-293-2135 | |
Monika Maximilliane Holbein, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Morgantown, WV 26506 Phone: 304-594-4000 | |
Nour Daboul, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Morgantown, WV 26506 Phone: 855-988-2273 |